What happens when this doctor goes keto and his LDL rockets to 574? We dive deep into the science, controversy, and personal decision-making behind the most misunderstood lipid profile in cardiology.

Learn about the risks of high cholesterol as you age, the importance of managing bad cholesterol, and alternative treatments ...

A new CRISPR-based one-off procedure that lowers "bad" cholesterol has been approved to enter Phase I human trial. If ...

This retrospective cohort analysis evaluated electronic medical records (Veterans Integrated Service Network 16) of adult patients with type 2 diabetes who had 2 or more measurements of low-density ...

This article was reviewed by Felix Gussone, MD. Key Takeaways: Cholesterol is a key building block for testosterone. Through ...

In patients with cardiovascular disease or who are at high risk for CVD, lerodalcibep significantly decreases LDL-C. Lerodalcibep significantly decreases low-density lipoprotein cholesterol (LDL-C) in ...

In another study of dyslipidemic patients not treated with hypolipidemic drugs (baseline examination), a very good correlation between LDL-C and apoB (r = 0.903; p < 0.001) was found. [66] In spite of ...

Findings showed the trial met the primary endpoint, with enlicitide demonstrating a statistically significantly meaningful reduction in LDL-C compared with placebo. Topline data were announced from a ...

Familial Hypobetalipoproteinemia (FHBL), caused by variants in the apolipoprotein B (APOB) gene, is a rare autosomal co-dominant monogenic disorder characterized by lifelong low plasma levels of total ...

Compared with placebo, obicetrapib lowered LDL-C by 33% at day 84 (P .0001). Topline results were announced from a phase 3 trial evaluating obicetrapib, an investigational low dose cholesterol ester ...

The prevalence of severely elevated low-density lipoprotein cholesterol (LDL-C) has declined in recent decades, but 1 in 17 US adults in a recent analysis had levels of LDL-C that would warrant ...

New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of standard of care WILMINGTON, Del.--(BUSINESS WIRE ...